Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauricio Tohen

Showing results (181-190 of 260) with videos related to

Pageof 26
Sort By:
Journal of Clinical Psychopharmacology|August 16, 2003
Olanzapine versus placebo in acute mania: treatment responses in subgroupsRoss J Baldessarini, John Hennen, Michael Wilson, et al.
Journal of Affective Disorders|April 16, 2019
Comparison of 71 bipolar disorder pharmacotherapies for kidney disorder risk: The potential hazards of polypharmacyAnastasiya Nestsiarovich, Berit Kerner, Aurélien J Mazurie, et al.
The American Journal of Psychiatry|May 2, 2006
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosisThomas H McGlashan, Robert B Zipursky, Diana Perkins, et al.
Archives of General Psychiatry|November 12, 2003
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depressionMauricio Tohen, Eduard Vieta, Joseph Calabrese, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|February 2, 2012
Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patientsRoss J Baldessarini, Leonardo Tondo, Gustavo H Vazquez, et al.
Archives of General Psychiatry|April 6, 2005
Antipsychotic drug effects on brain morphology in first-episode psychosisJeffrey A Lieberman, Gary D Tollefson, Cecil Charles, et al.
Depression and Anxiety|January 31, 2017
Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorderOle Köhler-Forsberg, Louisa Sylvia, Michael Thase, et al.
Acta Neuropsychiatrica|December 8, 2017
Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorderOle Köhler-Forsberg, Louisa Sylvia, Thilo Deckersbach, et al.
Bipolar Disorders|February 12, 2026
Potential Impact of Childhood Abuse on Quality of Life During Mood-Stabilising Treatment in Individuals Living With Bipolar DisorderAnna L Wrobel, Olivia M Dean, Mojtaba Lotfaliany, et al.
IEEE Journal of Biomedical and Health Informatics|March 3, 2025
Detecting Opioid Use Disorder in Health Claims Data With Positive Unlabeled LearningPraveen Kumar, Fariha Moomtaheen, Scott A Malec, et al.
Pageof 26

Showing results (181-190 of 260) with videos related to

Sort By:
Pageof 26
Journal of Clinical Psychopharmacology|August 16, 2003
Olanzapine versus placebo in acute mania: treatment responses in subgroupsRoss J Baldessarini, John Hennen, Michael Wilson, et al.
Journal of Affective Disorders|April 16, 2019
Comparison of 71 bipolar disorder pharmacotherapies for kidney disorder risk: The potential hazards of polypharmacyAnastasiya Nestsiarovich, Berit Kerner, Aurélien J Mazurie, et al.
The American Journal of Psychiatry|May 2, 2006
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosisThomas H McGlashan, Robert B Zipursky, Diana Perkins, et al.
Archives of General Psychiatry|November 12, 2003
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depressionMauricio Tohen, Eduard Vieta, Joseph Calabrese, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|February 2, 2012
Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patientsRoss J Baldessarini, Leonardo Tondo, Gustavo H Vazquez, et al.
Archives of General Psychiatry|April 6, 2005
Antipsychotic drug effects on brain morphology in first-episode psychosisJeffrey A Lieberman, Gary D Tollefson, Cecil Charles, et al.
Depression and Anxiety|January 31, 2017
Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorderOle Köhler-Forsberg, Louisa Sylvia, Michael Thase, et al.
Acta Neuropsychiatrica|December 8, 2017
Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorderOle Köhler-Forsberg, Louisa Sylvia, Thilo Deckersbach, et al.
Bipolar Disorders|February 12, 2026
Potential Impact of Childhood Abuse on Quality of Life During Mood-Stabilising Treatment in Individuals Living With Bipolar DisorderAnna L Wrobel, Olivia M Dean, Mojtaba Lotfaliany, et al.
IEEE Journal of Biomedical and Health Informatics|March 3, 2025
Detecting Opioid Use Disorder in Health Claims Data With Positive Unlabeled LearningPraveen Kumar, Fariha Moomtaheen, Scott A Malec, et al.
Pageof 26